Physician profile
Anthony M Cotronea
NPI 1821104662
$14,010.51
in general payments reported to CMS, 2019-2025
33 companies · $1,806 in 2025
The $1,806 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,725 · 2020: $961 · 2021: $2,564 · 2022: $2,292 · 2023: $1,492 · 2024: $2,171 · 2025: $1,806.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,469.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,469.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,687.39 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $1,414.58 | 2021-2025 | Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $1,259.00 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,158.95 | 2019-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,124.43 | 2019-2025 | Jardiance, Synjardy, Stiolto Respimat |
| Pfizer INC. | $1,089.80 | 2019-2025 | |
| Amgen INC. | $1,022.10 | 2019-2025 | Repatha, Repatha, Otezla |
| Lilly USA, LLC | $944.85 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $919.55 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $757.24 | 2019-2025 | Veozah |
| Allergan, INC. | $362.34 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $231.38 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $211.98 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $187.25 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Novartis Pharmaceuticals Corporation | $168.93 | 2019-2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $164.57 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $155.16 | 2024-2025 | Rexulti |
| Axsome Therapeutics, INC. | $153.86 | 2025 | Auvelity |
| Biohaven Pharmaceutical Holding Company LTD. | $150.58 | 2022 | |
| Abbott Laboratories | $101.58 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $97.01 | 2020-2021 | |
| Si-Bone, INC. | $81.43 | 2020 | |
| Microport Orthopedics INC | $77.93 | 2019 | |
| Amarin Pharma, INC. | $77.44 | 2019 | |
| Lundbeck LLC | $72.95 | 2024-2025 | Rexulti |
| Eisai INC. | $64.35 | 2019-2021 | |
| Abiomed | $60.54 | 2024-2025 | Impella |
| Mylan Specialty L.P. | $59.09 | 2019 | |
| Collegium Pharmaceutical, INC. | $55.68 | 2022-2023 | Xtampza |
| Sunovion Pharmaceuticals INC. | $31.14 | 2019 | |
| Phathom Pharmaceuticals, INC. | $30.61 | 2025 | Voquezna |
| Horizon Therapeutics Plc | $19.40 | 2021 | |
| Supernus Pharmaceuticals, INC. | $17.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Cotronea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.